<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This post hoc analysis reports that overall proportion of patients achieving a composite endpoint of HbA1c&lt;7.0% (&lt;53.0mmol/mol) without <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and <z:mp ids='MP_0005456'>weight gain</z:mp> was higher with vildagliptin than <z:chebi fb="0" ids="5383">glimepiride</z:chebi> after 2 years in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients inadequately controlled on <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy, regardless of age and duration of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>